Differential Immediate and Sustained Memory Enhancing Effects of Alpha7 Nicotinic Receptor Agonists and Allosteric Modulators in Rats
Open Access
- 9 November 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (11) , e27014
Abstract
The α7 nicotinic acetylcholine receptor (nAChR) is a potential target for the treatment of cognitive deficits in patients with schizophrenia, ADHD and Alzheimer's disease. Here we test the hypothesis that upregulation of α7 nAChR levels underlies the enhanced and sustained procognitive effect of repeated administration of α7 nAChR agonists. We further compare the effect of agonists to that of α7 nAChR positive allosteric modulators (PAMs), which do not induce upregulation of the α7 nAChR. Using the social discrimination test as a measure of short-term memory, we show that the α7 nAChR agonist A-582941 improves short-term memory immediately after repeated (7× daily), but not a single administration. The α7 nAChR PAMs PNU-120596 and AVL-3288 do not affect short-term memory immediately after a single or repeated administration. This demonstrates a fundamental difference in the behavioral effects of agonists and PAMs that may be relevant for clinical development. Importantly, A-582941 and AVL-3288 increase short-term memory 24 hrs after repeated, but not a single, administration, suggesting that repeated administration of both agonists and PAMs may produce sustained effects on cognitive performance. Subsequent [125I]-bungarotoxin autoradiography revealed no direct correlation between α7 nAChR levels in frontal cortical or hippocampal brain regions and short-term memory with either compound. Additionally, repeated treatment with A-582941 did not affect mRNA expression of RIC-3 or the lynx-like gene products lynx1, lynx2, PSCA, or Ly6H, which are known to affect nAChR function. In conclusion, both α7 nAChR agonists and PAMs exhibit sustained pro-cognitive effects after repeated administration, and altered levels of the α7 nAChR per se, or that of endogenous regulators of nAChR function, are likely not the major cause of this effect.Keywords
This publication has 41 references indexed in Scilit:
- Immediate and Sustained Improvements in Working Memory After Selective Stimulation of α7 Nicotinic Acetylcholine ReceptorsBiological Psychiatry, 2011
- TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophreniaBiochemical Pharmacology, 2009
- Activation and Desensitization of Nicotinic α7-type Acetylcholine Receptors by Benzylidene Anabaseines and NicotineThe Journal of Pharmacology and Experimental Therapeutics, 2009
- A role for LYNX2 in anxiety-related behaviorProceedings of the National Academy of Sciences, 2009
- RIC‐3 and nicotinic acetylcholine receptors: Biogenesis, properties, and diversityBiotechnology Journal, 2008
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- RIC‐3: a nicotinic acetylcholine receptor chaperoneBritish Journal of Pharmacology, 2008
- Nootropic α7 nicotinic receptor allosteric modulator derived from GABA A receptor modulatorsProceedings of the National Academy of Sciences, 2007
- Performance of α7 nicotinic receptor null mutants is impaired in appetitive learning measured in a signaled nose poke taskBehavioural Brain Research, 2005
- AR-R 17779, an α7 nicotinic agonist, improves learning and memory in ratsBehavioural Pharmacology, 1999